Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Randomized Double-Blind Positive-Controlled Ascending Dose Study to Evaluate the Safety and Immunogenicity of a Replication-Competent Adenovirus Serotype 4 Anthrax Vector Candidate Vaccines - Ad4-PA (Protective Antigen)and Ad4-PA-GPI (Glycosylphosphatidylinositol)

NCT01979406 is registered in ClinicalTrials.gov with Emergent BioSolutions as lead sponsor.

NCT NCT01979406
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01979406 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Randomized Double-Blind Positive-Controlled Ascending Dose Study to Evaluate the Safety and Immunogenicity of a Replication-Competent Adenovirus Serotype 4 Anthrax Vector Candidate Vaccines - Ad4-PA (Protective Antigen)and Ad4-PA-GPI (Glycosylphosphatidylinositol)
Lead sponsor
Emergent BioSolutions
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2013
Completion date
September 30, 2015
Enrollment
120 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

anthrax infection